ATAI Life Sciences ("ATAI" or the "Company"), a global biotechnology company builder founded by Christian Angermayer that envisions an end to mental illnesses, today announced the close of a $24 million convertible note financing round. Despite market turmoil caused by the COVID-19 pandemic, the round saw strong support from both new and existing investors.

 Founded by visionary entrepreneur Christian Angermayer, ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives.

ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors

Description

Company Information

Funding Insights

ATAI Life Sciences announces close of $24 million convertible note financing round and welcomes Jason Camm of Thiel Capital to Board of Directors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information